Next-Generation Antibody Therapeutics Market

Next-Generation Antibody Therapeutics Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Novel Antibody (Immunocytokines, Immunotoxins, and Radioisotope Immunoconjugates), Type of Target Indication (Acute Myeloid Leukemia, Bladder Cancer, Diffuse Large B-cell Lymphoma, Graft-versus-host disease, Melanoma Prostate Cancer and Soft-tissue Sarcoma), Type of Therapy (Combination Therapy and Monotherapy), Type of Route of Administration (Intratumoral, Intravenous, and Intravesical), Key Geographical Regions (North America, Europe and Asia Pacific, Latin America, Middle East and North Africa)

  • Lowest Price Guaranteed From USD 4,799

  • Pages
    235

  • View Count
    12265

Next-Generation Antibody Therapeutics Market Size Overview

The global next-generation antibody therapeutics market size is estimated to increase from USD 2.7 billion in 2024 to reach USD 6.3 billion by 2035, growing at a CAGR of 7.9% during the forecast period. 

Next-Generation Antibody Therapeutics Market, By Type of Novel Antibody, 2024-2035 (USD Billion)

The market for next-generation antibody therapeutics is poised to sprout out with an exceptional growth rate over this forecast period, mainly driven by the continuously growing number of cancer cases worldwide. According to the World Health Organization, cancer stands as the second most common cause of death at a global level. As per WHO’s recent report, cancer is projected to be responsible for about 10 million deaths every year. Although there are several traditional treatment options such as chemotherapy, radiation therapy, and surgery available that aid in managing disease progression and prevent the spread of malignant cells, however, these treatments have shown limited effectiveness specifically in relapsed / refractory cases. Moreover, the side effects of these conventional treatments impact patient's quality of life negatively. In response to this, several initiatives have been undertaken in the development of more effective targeted anti-cancer therapy.

With continuous advancements, novel antibody therapeutics have emerged as the most suitable treatment options for combating chronic diseases including various types of cancers. These therapies are designed with advanced antibody engineering technologies that aid in enhancing therapeutic effectiveness and target proteins that are expressed on the surface of the affected cells. Furthermore, concerning the growing demand for novel antibody therapies, leading market players are increasingly investing in the market for the development of next-generation antibody therapies and striving to leverage this lucrative opportunity by high capital investment to expand their competitive edge. Consequently, continued investment in R&D and commercialization efforts of market players are likely to fuel the market growth. However, the high investment in the development of novel antibody therapy and the high cost associated with the therapy treatment may limit the market potential.

Next-Generation Antibody Therapeutics Market Segmentation Insights

The market research report presents an in-depth analysis of the various companies that are engaged in the global market of next-generation antibody therapeutics, across different segments, as defined in the table below:

Global Next-Generation Antibody Therapeutics Market: Report Attributes / Market Segmentations

Key Report Attribute Details
Historical Trend 2018-2023
Base Year 2023
Forecast Period 2024-2035
Market Size by 2035 USD 6.3 Billion
CAGR 7.9%
Type of Novel Antibody
  • Immunocytokines
  • Immunotoxins 
  • Radioisotope Immunoconjugates
Type of Target Indication
  • Acute Myeloid Leukemia
  • Bladder Cancer
  • Diffuse Large B-cell Lymphoma
  • Graft-versus-host disease
  • Melanoma Prostate Cancer 
  • Soft-tissue Sarcoma
Type of Therapy 
  • Combination Therapy 
  • Monotherapy
Type of Route of Administration
  • Intratumoral
  • Intravenous
  • Intravesical
Key Geographical Regions
  • North America
  • Europe
  • Asia Pacific
  • Latin America, 
  • Middle East and North Africa
Key Companies Profiled
  • Actinium Pharmaceuticals
  • Molecular Templates 
  • Philogen
  • Roche
  • Seagen 
  • Sesen bio
  • Telix Pharmaceuticals
  • Y-mAbs Therapeutics
(A full list of operating companies captured is and available in the report)
PowerPoint Presentation
(Complimentary)
Available
Customization Scope 15% Free Customization 
Excel Data Packs
(Complimentary)
  • Market Landscape Analysis for Novel Antibody Therapy 
  • Clinical Trial Analysis
  • Partnerships and Collaborations Analysis
  • Company Competitiveness Analysis
  • Market Forecast and Future Opportunity Analysis

One of the key objectives of this market report was to estimate the current market size, opportunity, and future growth potential of the next-generation antibody therapeutics market, over the forecast period. Based on multiple parameters, likely adoption trends, and through primary validations, we have provided an informed estimate of the market evolution during the forecast period 2024-2035.

The market report also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as type of novel antibody (immunocytokines, immunotoxins and radioisotope immunoconjugates), type of target indication (acute myeloid leukemia, bladder cancer, diffuse large b-cell lymphoma, graft-versus-host disease, melanoma prostate cancer and soft-tissue sarcoma), type of therapy (combination therapy and monotherapy), type of route of administration (intratumoral, intravenous, and intravesical),  and key geographical regions (North America, Europe and Asia Pacific, Latin America, Middle East, North Africa and rest of the world). 

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Next-Generation Antibody Therapeutics Market Share Insights

Market Share by Type of Antibody

Based on the type of novel antibody, the next-generation antibody therapeutics market is split into Immunocytokines, Immunotoxins, and Radioisotope Immunoconjugates. As per market research, radioisotope immunoconjugates dominate the segment with 58% of the total next-generation antibody therapeutics market share. Immunocytokines drive the market growth with 47% CAGR over this forecast period. Immunotoxins are FDA-approved antibodies that have shown effective cytotoxicity that treats multiple hematological malignancies, significantly driving the growth of the market.

Market Share by Target Indication

Based on the type of target indication, the global next-generation antibody therapeutics industry is categorized into Acute Myeloid Leukemia, Bladder Cancer, Diffuse Large B-cell Lymphoma, Graft-versus-host disease, Melanoma Prostate Cancer and Soft-tissue Sarcoma. As per market research, melanoma prostate cancer holds 35% of the market share and escalates the market growth with 47% CAGR over this forecast period. The mounting number of prostate cancer cases and growing demand for effective treatment are anticipated to drive the next-generation antibody therapeutics market growth during this forecast period.

Market Share by Type of Therapy

Based on the type of therapy, the global next-generation antibody therapeutics market is bifurcated into Combination Therapy and Monotherapy. According to a market review, the monotherapy segment captures 96% of share, leading the market growth. Furthermore, combination therapy augments the market growth at a CAGR of 45%. The characteristics of dual or more drug treatment or modalities of combination therapy in achieving additive effects contribute to the higher demand for combination therapy, fostering market growth.

Market Share by Route of Administration

Based on the type of route of administration, the global next-generation antibody therapeutics market is divided into Intratumoral, Intravenous, and Intravesical. As per our projection, the intravenous segment captures 69% of the next-generation antibody therapeutics market share and will continue to dominate the market till 2035. Owing to being the most common route of administration and best suitable for the systematic distribution of medication to treat disseminated disease, the intravenous is anticipated to continue to drive the growth of the market during this projection timeframe. Additionally, Intravesical route is anticipated to elevate the market with a CAGR of 39% by 2035 over this forecast period. 

Market Share by Key Geographical Regions

This segment highlights the distribution of the next-generation antibody therapeutics industry across various geographies, including North America, Europe, Asia-Pacific, Latin America, Middle East, and North Africa. As per market review, North America accounts for 76% of the next-generation antibody therapeutics market shares and is estimated to be a leading region in the global market.. The high investment & support from public and private organizations in medical research and drug discovery substantially drive the market growth in the region.

Next-Generation Antibody Therapeutics Market: Key Insights

The “Next-Generation Antibody Therapeutics Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the companies involved in the next-generation antibody therapeutic development. Key takeaways of the market size, competitive landscape, and geographical regions in the market report are briefly discussed below.

Competitive Landscape of Next-Generation Antibody Therapeutics Manufacturing Companies 

At present, nearly 55 pharmaceutical companies are operating in the next-generation antibody therapeutics market along with other giant market players worldwide. In this competitive industry, these companies compete for market share by focusing on innovation, and higher capital investment in research and development for novel antibody therapies. Some of the leading players in the next-generation antibody therapeutics market are Actinium Pharmaceuticals, Molecular Templates, Philogen, Roche, Seagen, Sesen Bio, Telix Pharmaceuticals, and Y-mAbs Therapeutics. 

Among these key players, around 56% of the leading companies are based in North America. In addition, large companies are currently dominating the market for next-generation antibody therapeutics in terms of revenue, comprising 27% of the market share. Furthermore, these key players adopt collaboration & partnership strategies to expand their product portfolio and global reach. For instance, in November 2023, Boehringer Ingelheim and IBM collaborated to discover novel candidate antibodies by using IBM’s model technology, aiming for the development of efficient therapeutics.

Trends Analysis in Next-Generation Antibody Therapeutics Market: Rising Implementation of ADC Technology Widen Next-Generation Antibody Therapeutic Market Scope

In recent years, the market for next-generation antibody therapeutics has evolved with the growing penetration of technological advancement. About this, the inflating adoption of ADC technology reflects a key trend in the oncology field, gaining traction. Antibody drug conjugate (ADC) comprises an antibody, a linker, and a payload, and this combination delivers the cytotoxic agent selectively to cancer cells expressing the target antigen. This targeted approach reduces damage to healthy cells, minimizes off-target effects, and enhances the therapeutic effects as compared to traditional chemotherapy. Consequently, constant technological developments in ADC research and development activity are likely to generate lucrative opportunities in expanding the potential growth of the market. For instance, in March 2024, Gilead Sciences and Merus N.V. announced a research collaboration, option, and license agreement for discovering a novel dual tumor-associated antigen (TAA) targeting tri-specific antibodies.

Market Size Analysis: North America Will Dominate the Next-Generation Antibody Therapeutics Market

The high prevalence of chronic diseases such as various types of cancers and infectious diseases significantly raises the demand for novel antibody therapies, which is likely to augment the market demand for next generation / advanced antibody therapeutics. The growing clinical trials and regulatory approval for next-generation antibody therapeutics coupled with major pharmaceutical companies’ efforts in advanced drug discovery is anticipated to propel the market growth in North America during this forecast period.

Additionally, Asia Pacific is projected to register a significant CAGR and is likely to contribute to accelerating the market growth during this forecast. The driving factors of the market growth in the region can be attributed to the expansion of the market with increasing strategic partnerships and collaborations between global and local market players. Furthermore, a surge in healthcare spending with an inflating patient population, enhanced government support for novel drug discovery, and an increasing number of pharmaceutical companies focused on R&D are attributed to lifting the next-generation antibody therapeutics market in the Asia Pacific.

Key Players in Next-Generation Antibody Therapeutics Market 

Examples of key companies engaged in the next-generation antibody therapeutics market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Actinium Pharmaceuticals, Molecular Templates, Philogen, Roche, Seagen, Sesen bio, Telix Pharmaceuticals and Y-mAbs Therapeutics. This market report includes an easily searchable Excel database of all the companies who have adopted the next-generation antibody therapeutics market.

Next-Generation Antibody Therapeutics Market Report Coverage

  • A general overview of novel antibody therapies including information on the different types of novel antibody therapies. In addition, the chapter presents details on the novel antibody therapies (antibody-directed enzyme prodrug therapy, TCR like antibodies, radioisotope immunoconjugates, immunotoxins, intracellular antibody and immunocytokines). It also features information on developmental approaches of novel antibody therapies, limitations, and future of novel antibody therapies.
This image highlights the context of Novel Antibody Therapies Market report. Given the potential of novel antibody therapies to treat multiple oncological disorders, such therapies have generated significant interest within the medical research community This image provides Development Pipeline of Immunocytokines. Presently, around 55 players across the globe are engaged in developing novel antibody therapies for the treatment of multiple disease indications; majority of the large players are based in North America This image presents current market landscape of Immunocytokines, Immunotoxins and Radioisotope Immunoconjugates. A relatively larger proportion of Immunocytokines, and Immunotoxins are in advanced stages of development; more than 20% of the Radioisotope Immunoconjugate candidates are 131-Iodine radioisotopes
  • A detailed review of the current market landscape of immunocytokines, based on several relevant parameters such as status of development (phase III, phase II, phase I and preclinical stage), mechanism of action (inhibition, modulation and stimulation), type of cytokine, type of antigen / format, dosing frequency, type of therapy (monotherapy and combination therapy), mode of administration (injection and infusion), route of administration (intravenous, intratumoral and subcutaneous), type of therapy and  target disease indication(s). 
  • A detailed review of the current market landscape of immunotoxins based on several relevant parameters such as status of development (marketed, BLA registration, phase III, phase II phase I and preclinical stage), mechanism of action (inhibition, modulation and stimulation), type of toxin, dosing frequency, type of therapy (monotherapy and combination therapy), mode of administration (injection and infusion), immunotoxin target, route of administration (intravenous, intravesical, intraperitoneal, intratumoral and intrathecal), and target disease indication(s). 
  • A detailed review of the current market landscape of radioisotope immunoconjugates based on several relevant parameters such as status of development (marketed, phase III, phase II phase I and preclinical stage), type of radioisotope, route of administration (Intravenous, intracerebroventricular and intraperitoneal), type of therapy (monotherapy and combination therapy), dosing frequency, mode of administration (injection and infusion) and target disease indication(s). In addition, the chapter includes a list of novel antibody therapies with special designations. Further, the chapter presents a list of players developing novel antibody therapies along with information on their year of establishment, company size and location of headquarters. 
  • Elaborate profiles of the key players engaged in the development of novel antibody therapies (shortlisted on the basis of number of drugs). Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio and a section on recent developments and an informed future outlook.
This image provides information about completed, ongoing and planned clinical studies of various novel antibody therapies. 550+ clinical trials related to novel antibody therapies have been registered till date; majority (44%) of these trials were / are being conducted across various clinical sites based in Europe This image presents review of close to 1,135 peer-reviewed, scientific articles related to novel antibody therapies. In the past few years, more than 570 articles related to novel antibody therapies have been published by several eminent authors in high-impact journals; more than 50% of the articles were published in 2021 This image provides information on patents that have been filed / granted related to novel antibody therapies. Since 2017, over 4,600 patents have been granted / filed for various novel antibody therapies, demonstrating the rising interest and rapid pace of research in this field
  • An in-depth analysis of completed, ongoing and planned clinical studies of various novel antibody therapies, highlighting prevalent trends across different parameters, such as current trial status, trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator, study design, leading industry and non-industry players (in terms of number of trials conducted), key indication(s), type of treatment, type of drug, emerging focus areas and regional distribution of trials.
  • A detailed review of more than 570 peer-reviewed, scientific articles related to research on novel antibody therapies, which have been published since 2017, based on parameters, such as year of publication, type of article, emerging focus areas, top authors, key journals, most popular publisher and copyright holders.
  • An insightful analysis of the patents filed / granted for novel antibody therapies, between 2017- 2021, based on various relevant parameters, such as patent publication year, type of patent, geographical location, CPC symbols, type of applicant, patent age, emerging focus areas, leading individual assignees, industry and non-industry players (in terms of number of patents granted / filed) and patent characteristics. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis.
  • An analysis of the partnerships that have been established in next-generation antibody therapeutics market since 2018, covering instances of acquisition, clinical trial agreement, commercialization agreement, distribution agreement, antibody manufacturing agreement, product development agreement, product development and commercialization agreement, research and development agreement, supply agreement and other relevant type of deals.
  • An analysis of big pharma players engaged in the field of next-generation antibody therapeutics market, featuring various insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on several relevant parameters, such as number of therapeutics under development, type of novel antibody, status of development, number of target indications, number of partnerships, number of patents and years of experience.
This image highlights the partnership activity undertaken by players engaged in the field of novel antibody therapies. The growing interest is also evident from the rise in partnership activity, since 2020; a major proportion of the deals were signed by companies based in North America This image provides information on the current and future market trends and potential growth of Novel Antibody Therapies Market. With the rising demand for new therapeutic modalities with high efficacy, the novel antibody therapies market for late-stage drugs is likely to grow at an annualized rate of 36% till 2035 This image highlights the market segments of Novel Antibody Therapies Market. The opportunity associated with novel antibody therapies market is likely to be well distributed across various types of therapies, route of administration and key geographical regions

Recent Developments in Next-Generation Antibody Therapeutics Market

In the past few years, the market for next-generation antibody therapeutics has been blooming. Several ongoing innovations and developments are projected to boost market potential. These developments, even if they took place post the release of our market report, substantiate the overall trends that have been outlined in our next-generation antibody therapeutics market analysis.

  • In February 2024, Ono Pharmaceutical announced a partnership with Epsilon Molecular Engineering (EME) to advance the drug discovery of the variable heavy domain of heavy chain (VHH) antibodies, aiming to develop new therapeutic agents.
  • In July 2023, TVM Capital Life Science in collaboration with Tillotts Pharma invested USD 28 million in Mage Biologics with an aim to develop innovative oral antibody therapy for ulcerative colitis. 
  • In May 2023, Lassen Therapeutics published Phase I Data on LASN01, an IL-11 receptor-blocking antibody, for treatment of pulmonary fibrosis, at the American Thoracic Society 2023 Annual Meeting. 
  • In April 2023, Genmab entered into a collaboration with argenx in order to discover, develop and commercialize novel therapeutic antibodies with applications in immunology and oncology.
     

Frequently Asked Questions

Question 1: What is antibody therapy?

Answer: Antibody therapies include different classes of antibodies, which are capable of killing or inhibiting disease-causing agents. These therapies have demonstrated the capability to selectively target and eliminate tumor cells.

Question 2: What is the next-generation antibody therapeutics market size?

Answer: The novel antibody therapy market size is estimated to reach $6.3 billion by 2035.

Question 3: What is the projected market growth of the next-generation antibody therapeutics market?

Answer: The novel antibody therapy market is expected to grow at compounded annual growth rate (CAGR) of 7.9% during the forecast period 2024 - 2035.

Question 4: Who are the leading companies in the novel antibody therapy market?

Answer: Actinium Pharmaceuticals, Molecular Templates, Philogen, Roche, Seagen, Sesen bio, Telix Pharmaceuticals and Y-mAbs Therapeutics.

Question 5: How many next-generation antibody therapeutics have been approved for oncological disorders?

Answer: Six novel antibody therapies have been approved for various oncological disorders till date.

Question 6: Which region is the hub for players developing next-generation antibody therapeutics?

Answer: North America presently harbors the majority of the players providing novel antibody therapy, with close to 55% of the companies established in this region.

Question 7: How many clinical trials have been conducted for evaluating next-generation antibody therapeutics?

Answer: Till date, over 550 clinical trials have been conducted for evaluating novel antibody therapy, highlighting the ongoing research in this field.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com